Cancer Genetics, Inc. (CGIX)

Check out top investors' recommendation for CGIX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Cancer Genetics, Inc., an early-stage diagnostics company, focuses on the development and commercialization of proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray test for the detection of chromosomal abnormalities observed in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and Diffuse Large B-cell Lymphoma; molecular testing to analyze DNA and RNA to follow progression of disease and response to therapy at the genetic level; cytogenetics testing, a series of methods for analyzing human chromosomes to identify malignancy; fish testing, an analysis of abnormalities at the chromosomal and gene levels; flow cytometry testing, an immuno pheno - type analysis of specific markers inside cells; histology testing, a microscopic examination of stained tissue sections; cytology testing, a non-gynecological fluid preparation for microscopic evaluations by a pathologist; and IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. It offers DNA-based cancer diagnostics and services medical institutions. The company?s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also provides a range of non-proprietary oncology-focused tests and laboratory services that offer critical genomic information to healthcare professionals, as well as biopharma and biotech. The company was founded in 1999 and is headquartered in Rutherford, New Jersey.
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ram Selvaraju Aegis Capital Buy   Sep 19, '18     3.00  Sep 19, '19  N/A 
Ram Selvaraju Aegis Capital Buy   Aug 15, '18     3.00  Aug 15, '19  N/A 
Ram Selvaraju Aegis Capital Buy   May 29, '18     3.00  May 29, '19  N/A 
Ram Selvaraju Aegis Capital Buy   Jan 16, '18     6.00  Jan 16, '19  N/A 
Ram Selvaraju Aegis Capital Buy   Nov 29, '17     6.00  Nov 29, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Sep 21, '17     6.00  Sep 21, '18  N/A 
Ram Selvaraju Aegis Capital Buy   Aug 15, '17     6.00  Aug 15, '18  N/A 
Raymond Myers The Benchmark Company Buy   Jun 26, '17     6.00  Jun 26, '18  N/A 
Paul Knight Credit Agricole Securities Buy   Apr 09, '15   8.78    Apr 09, '16  -69.70% 
Charles Graham Unaffiliated Buy   Feb 28, '14   18.86  42.00  Feb 28, '15  -53.55% 
Ram Selvaraju Aegis Capital Buy   Feb 10, '14   16.88    Feb 10, '15  -60.13% 
Ram Selvaraju Aegis Capital Buy   Nov 14, '13   14.97    Nov 14, '14  -56.05%